Covered recipient · General Payments record
VAN MORRIS
General Payments · PY2019–2025
$60,427.68
- Reported across 74 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $24,630.31 | 9 |
| Travel and Lodging | $2,560.08 | 9 |
| Honoraria | $1,650.00 | 1 |
| Food and Beverage | $1,005.54 | 15 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $9,751.31 | 8 |
| BioNTech SE | $5,579.98 | 7 |
| GlaxoSmithKline, LLC. | $4,353.32 | 7 |
| E.R. Squibb & Sons, L.L.C. | $3,162.36 | 3 |
| ABBVIE INC. | $2,790.77 | 3 |
| PFIZER INC. | $2,231.72 | 2 |
| Exelixis Inc. | $1,825.00 | 2 |
| IMMUNITYBIO, INC. | $83.47 | 1 |
| Genentech USA, Inc. | $68.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2025 20192020202220232024
Record-level detail is published for PY2025; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.22 | 06/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203146978 | CMS |
| ABBVIE INC. | $110.22 | 06/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1203146984 | CMS |
| ABBVIE INC. | $2,658.33 | 06/06/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1203146989 | CMS |
| BioNTech SE | $182.43 | 05/28/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1249001579 | CMS |
| BioNTech SE | $327.55 | 05/28/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1249001587 | CMS |
| BioNTech SE | $125.00 | 05/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249001592 | CMS |
| BioNTech SE | $22.80 | 05/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249001595 | CMS |
| BioNTech SE | $181.70 | 05/31/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1249001584 | CMS |
| BioNTech SE | $28.00 | 05/31/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1249001598 | CMS |
| BioNTech SE | $4,712.50 | 06/16/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1249001609 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,250.00 | 06/13/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1184666804 | CMS |
| E.R. Squibb & Sons, L.L.C. | $12.36 | 10/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1184666925 | CMS |
| E.R. Squibb & Sons, L.L.C. | $900.00 | 10/20/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1184666873 | CMS |
| Exelixis Inc. | $1,650.00 | 05/22/2025 | Honoraria | Undisputed | 06/30/2026 | 1218806993 | CMS |
| Exelixis Inc. | $175.00 | 05/31/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1218806990 | CMS |
| Genentech USA, Inc. | $68.00 | 06/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1211603820 | CMS |
| GlaxoSmithKline, LLC. | $545.00 | 02/24/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1190602233 | CMS |
| GlaxoSmithKline, LLC. | $124.84 | 03/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190626036 | CMS |
| GlaxoSmithKline, LLC. | $208.45 | 03/24/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1190661273 | CMS |
| GlaxoSmithKline, LLC. | $25.68 | 03/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191028589 | CMS |
| GlaxoSmithKline, LLC. | $2,986.98 | 04/15/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1190415303 | CMS |
| GlaxoSmithKline, LLC. | $400.00 | 08/22/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1190741083 | CMS |
| GlaxoSmithKline, LLC. | $62.37 | 10/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190614020 | CMS |
| IMMUNITYBIO, INC. | $83.47 | 04/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233174056 | CMS |
| Incyte Corporation | $1,370.00 | 09/19/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1226001205 | CMS |
| Incyte Corporation | $266.46 | 11/13/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1225999901 | CMS |
| Incyte Corporation | $197.00 | 11/13/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1225999903 | CMS |
| Incyte Corporation | $509.20 | 11/13/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1225999911 | CMS |
| Incyte Corporation | $55.67 | 11/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1225999907 | CMS |
| Incyte Corporation | $18.19 | 11/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1225999909 | CMS |
| Incyte Corporation | $142.29 | 11/14/2025 | Travel and Lodging | Undisputed | 06/30/2026 | 1225999913 | CMS |
| Incyte Corporation | $7,192.50 | 12/18/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1225999905 | CMS |
| PFIZER INC. | $71.72 | 05/31/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1230141457 | CMS |
| PFIZER INC. | $2,160.00 | 06/17/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1230465685 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2022, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.